DD295155A5 - Verfahren zur herstellung von l-carnitin-magnesium-zitrat - Google Patents

Verfahren zur herstellung von l-carnitin-magnesium-zitrat Download PDF

Info

Publication number: DD295155A5
Authority: DD; German Democratic Republic
Prior art keywords: carnitine; magnesium; citrate; solution; magnesium citrate
Prior art date: 1989-06-14

Application number

DD90341543A

Other languages

German (de)

English (en)

Inventor

Thomas Scholl

Willibald F Kohl

Original Assignee

��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-14

Filing date

1990-06-12

Publication date

1991-10-24

1990-06-12 Application filed by ��@��k�� filed Critical ��@��k��

1991-10-24 Publication of DD295155A5 publication Critical patent/DD295155A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 14
VIOYPGDQEDDCJB-UUCJDPIKSA-H trimagnesium;2-hydroxypropane-1,2,3-tricarboxylate;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound [Mg+2].[Mg+2].[Mg+2].C[N+](C)(C)C[C@H](O)CC([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O VIOYPGDQEDDCJB-UUCJDPIKSA-H 0.000 title claims abstract description 12
230000008569 process Effects 0.000 title claims abstract description 9
238000002360 preparation method Methods 0.000 title claims abstract description 7
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 19
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 18
150000002681 magnesium compounds Chemical class 0.000 claims abstract description 7
239000011777 magnesium Substances 0.000 claims description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
239000000347 magnesium hydroxide Substances 0.000 claims description 5
229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 5
238000001694 spray drying Methods 0.000 claims description 5
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
238000009835 boiling Methods 0.000 claims description 2
RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims description 2
229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
239000000395 magnesium oxide Substances 0.000 claims description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
229960005336 magnesium citrate Drugs 0.000 claims 1
239000004337 magnesium citrate Substances 0.000 claims 1
235000002538 magnesium citrate Nutrition 0.000 claims 1
PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 1
239000013543 active substance Substances 0.000 abstract description 2
235000014268 sports nutrition Nutrition 0.000 abstract description 2
230000000144 pharmacologic effect Effects 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
229910052749 magnesium Inorganic materials 0.000 description 8
229940091250 magnesium supplement Drugs 0.000 description 8
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
208000007101 Muscle Cramp Diseases 0.000 description 2
206010003119 arrhythmia Diseases 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
239000000843 powder Substances 0.000 description 2
206010058892 Carnitine deficiency Diseases 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
238000000441 X-ray spectroscopy Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000011128 cardiac conduction Effects 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
229960001983 magnesium aspartate Drugs 0.000 description 1
-1 magnesium compounds magnesium hydroxide Chemical class 0.000 description 1
QWLHYYKDLOVBNV-UHFFFAOYSA-L magnesium orotate Chemical compound [Mg+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 QWLHYYKDLOVBNV-UHFFFAOYSA-L 0.000 description 1
229960000407 magnesium orotate Drugs 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000003387 muscular Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nutrition Science (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicinal Preparation (AREA)

DD90341543A 1989-06-14 1990-06-12 Verfahren zur herstellung von l-carnitin-magnesium-zitrat DD295155A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH222189		1989-06-14

Publications (1)

Publication Number	Publication Date
DD295155A5 true DD295155A5 (de)	1991-10-24

Family

ID=4228693

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD90341543A DD295155A5 (de)	1989-06-14	1990-06-12	Verfahren zur herstellung von l-carnitin-magnesium-zitrat

Country Status (9)

Country	Link
US (1)	US5071874A (fr)
EP (1)	EP0402755B1 (fr)
JP (1)	JP3023919B2 (fr)
AT (1)	ATE93511T1 (fr)
CA (1)	CA2018137C (fr)
DD (1)	DD295155A5 (fr)
DE (1)	DE59002438D1 (fr)
DK (1)	DK0402755T3 (fr)
ES (1)	ES2058680T3 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4027927A1 (de) *	1990-09-04	1992-03-05	Bayer Ag	Brausekomponente und verfahren zu ihrer herstellung
RU2038077C1 (ru) *	1992-06-26	1995-06-27	Нонна Дмитриевна Кислякова	Средство, обладающее адаптогенной активностью
AU1780395A (en) *	1994-05-02	1995-11-09	Omeara (Proprietary) Limited	Amino acid, carnitine and magnesium supplementation
US5817329A (en) *	1997-02-28	1998-10-06	Gardiner; Paul T.	Nutritional supplement for increased muscle size and strength for body builders
IT1291126B1 (it) *	1997-04-01	1998-12-29	Sigma Tau Ind Farmaceuti	Composizioni solide atte alla somministrazione orale comprendenti sali non igroscopici della l-carnitina e delle alcanoil l-carnitine
IT1291133B1 (it) *	1997-04-07	1998-12-29	Sigma Tau Ind Farmaceuti	Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio tartrato
IT1291134B1 (it) *	1997-04-08	1998-12-29	Sigma Tau Ind Farmaceuti	Composizioni solide atte alla somministrazione orale comprendenti una alcanoil l-carnitina magnesio citrato
IT1291143B1 (it) *	1997-04-18	1998-12-29	Sigma Tau Ind Farmaceuti	Composizioni solide atte alla somministrazione orale comprendenti l-carnitina colina tartrato o una alcanoil l-carnitina colina
IT1290600B1 (it) *	1997-04-30	1998-12-10	Sigma Tau Ind Farmaceuti	Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio fumarato
US20030176514A1 (en) *	2000-08-29	2003-09-18	Martin Fuhrmann	Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate
DE10113446A1 (de)	2001-03-19	2002-09-26	Schwarzkopf Gmbh Hans	Haarbehandlungsmittel mit Betainen
ITRM20020055A1 (it) *	2002-02-04	2003-08-04	Aldo Fassi	Sali metallici di carnitine, integratori dietetici/nutritivi che li contengono e kit dietetici per contrastare disturbi sessuali in soggetti
ITMI20030315A1 (it) *	2003-02-21	2004-08-22	Vama Farmacosmetica S R L	Sale di carnitina, preliposoma che lo contiene e formulato dermocosmetico per uso topico a base del detto sale di carnitina.
AU2006265280B2 (en) *	2005-07-05	2011-07-14	Lonza Ag	Spray-drying process for producing a dry carnitine powder or granulate
DE102005062360A1 (de)	2005-12-23	2007-06-28	Henkel Kgaa	Haarfärbeverfahren
EP2253307B1 (fr) *	2006-05-12	2015-07-08	Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG	L-carnitine pour la supression de la cristallisation
EP1862163A1 (fr) *	2006-05-12	2007-12-05	Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG	L-carnitine pour la supression de la cristallisation
CN101209975B (zh)	2006-12-29	2010-12-01	沈阳科硕营养科技有限公司	左旋肉碱富马酸钙及其制备方法与用途
EP2206440A1 (fr) *	2008-12-24	2010-07-14	Taminco	Processus de préparation d'une poudre à écoulement libre d'un composé d'ammoniac quaternaire déliquescent
CN102911069A (zh) *	2011-08-04	2013-02-06	广州市奥海生物科技有限公司	左旋肉碱柠檬酸钙及其制备方法与用途
CN102911068A (zh) *	2011-08-04	2013-02-06	广州市奥海生物科技有限公司	左旋肉碱l-苹果酸盐及其制备方法与用途
CN102911067A (zh) *	2011-08-04	2013-02-06	广州市奥海生物科技有限公司	左旋肉碱丙酮酸盐及其制备方法与用途
CN103922949A (zh) *	2014-04-29	2014-07-16	吉林大学	一种亮氨酸鳌合钙粉及加工方法
KR101721145B1 (ko) *	2015-07-29	2017-03-29	제너럴바이오(주)	Ｌ-카르니틴 구연산 마그네슘을 포함하는 배변촉진 겸용 다이어트용 식품 조성물
IL261670B (en) *	2018-09-06	2019-06-30	Tudu Holdings Ltd	Magnesium-containing formulation and uses thereof
CN111990574A (zh) *	2020-09-18	2020-11-27	内蒙古精晶生物科技有限公司	一种左旋肉碱营养泡腾片

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE23217C (de) *		1900-01-01	F. E. CANDA in New-York	Zapfenlager aus Amalgam
FR4608M (fr) *	1965-04-02	1966-11-21
GB1153640A (en) *	1967-04-10	1969-05-29	Soc D Etudes Prod Chimique	A Carnitin Salt
US3810994A (en) *	1972-06-01	1974-05-14	Ethyl Corp	Method and composition for treating obesity
US4172072A (en) *	1977-10-20	1979-10-23	Ashmead H H	Buffered enzymatically produced metal proteinates
DE2903558C2 (de) *	1978-02-03	1994-09-01	Sigma Tau Ind Farmaceuti	Verwendung von L-Carnitin
IT1142201B (it) *	1980-06-24	1986-10-08	Sigma Tau Ind Farmaceuti	Procedimento per la produzione enzimatica di l-carnitina
JPS57126420A (en) *	1981-01-26	1982-08-06	Eiji Murakami	Drug for digestive organ
EP0150688B1 (fr) *	1983-12-28	1987-04-22	Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.	Sels de L-carnitine et d'alcanoyl L-carnitines et procédé pour leur préparation
US4537772A (en) *	1984-05-02	1985-08-27	Merck & Co., Inc.	Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
US4855289A (en) *	1984-06-04	1989-08-08	Wester Per O	Combination of two active substances
IT1209564B (it) *	1984-06-29	1989-08-30	Magis Farmaceutici	Derivati della l-carnitina o di l-acil carnitina.
IT1190280B (it) *	1986-04-24	1988-02-16	Sigma Tau Ind Farmaceuti	Procedimento per la preparazione di gamma-butirrobetaina
US4871550A (en) *	1986-09-05	1989-10-03	Millman Phillip L	Nutrient composition for athletes and method of making and using the same
US4895980A (en) *	1988-01-05	1990-01-23	Mission Pharmacal Company, Inc.	Method of manufacturing magnesium potassium citrate
JP3604736B2 (ja) *	1994-06-30	2004-12-22	株式会社トーア	外壁工法
JPH0824889A (ja) *	1994-07-19	1996-01-30	Hitachi Ltd	噴水曝気型水質浄化装置

1990
- 1990-06-01 CA CA002018137A patent/CA2018137C/fr not_active Expired - Lifetime
- 1990-06-06 ES ES90110725T patent/ES2058680T3/es not_active Expired - Lifetime
- 1990-06-06 DK DK90110725.0T patent/DK0402755T3/da active
- 1990-06-06 DE DE90110725T patent/DE59002438D1/de not_active Expired - Lifetime
- 1990-06-06 AT AT90110725T patent/ATE93511T1/de not_active IP Right Cessation
- 1990-06-06 EP EP90110725A patent/EP0402755B1/fr not_active Expired - Lifetime
- 1990-06-11 JP JP2152507A patent/JP3023919B2/ja not_active Expired - Fee Related
- 1990-06-12 DD DD90341543A patent/DD295155A5/de not_active IP Right Cessation
- 1990-06-13 US US07/537,989 patent/US5071874A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP3023919B2 (ja)	2000-03-21
EP0402755A3 (fr)	1991-01-16
JPH0324010A (ja)	1991-02-01
ATE93511T1 (de)	1993-09-15
EP0402755B1 (fr)	1993-08-25
US5071874A (en)	1991-12-10
DK0402755T3 (da)	1993-10-04
CA2018137A1 (fr)	1990-12-14
CA2018137C (fr)	2000-01-11
ES2058680T3 (es)	1994-11-01
EP0402755A2 (fr)	1990-12-19
DE59002438D1 (de)	1993-09-30

Legal Events

Date	Code	Title	Description
1999-02-18	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DD295155A5 (de)	1991-10-24	Verfahren zur herstellung von l-carnitin-magnesium-zitrat
DE602004011790T2 (de)	2009-03-05	Meldoniumsalze, verfahren zu deren herstellung und auf ihnen basierende pharmazeutische zusammensetzung
DE19707694A1 (de)	1998-08-27	Kreatin-ascorbate und Verfahren zu deren Herstellung
CH644263A5 (de)	1984-07-31	Fuer kosmetische zwecke verwendbare praeparate und verfahren zur herstellung der wirkstoffe dieser praeparate.
CH420120A (de)	1966-09-15	Verfahren zur Herstellung von Metallsalzen der a-Hydroxy-y-methylmercaptobuttersäure
CH635344A5 (en)	1983-03-31	Process for the preparation of d,l-5-methyltetrahydrofolic acid and its salts
DE19929993C2 (de)	2001-07-05	Kreatin-alpha-ketoglutarate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE2301540C3 (fr)	1979-07-12
DE2002385B2 (de)	1975-03-20	Verfahren zur Herstellung von Lactulose-Konzentrat
DE60008392T2 (de)	2004-11-25	Nicht-hygroskopische salze aktiver inhaltsstoffe, die therapeutische und/oder ernährungsphysiologische eigenschaften haben und oral verabreichbare zusammensetzungen, die diese enthalten
DE2522218C3 (de)	1981-04-02	Zusammensetzung für die Human- oder Veterinärmedizin, Methylaminderivate und Verfahren zu deren Herstellung
DE69911021T2 (de)	2004-04-01	Nicht-hygroskopische salze des l-karnitines und der alkanoyl-karnitine enthaltende feste zusammensetzungen zur oralen verabreichung
DE1493618A1 (de)	1969-07-10	Cumarinderivate und ein Verfahren zu ihrer Herstellung
DE2622977C2 (de)	1985-04-11	p-Chlorphenoxyisobutyryl-glycinamid, Verfahren zu dessen Herstellung und diese Verbindung enthaltendes, den Fettstoffwechsel förderndes Mittel
DE2609533B2 (de)	1980-02-21	Verfahren zur Extraktion von Wirkstoffen, insbesondere von Heterosidestern der Kaffeesäure, sowie diese Verbindungen enthaltende Arzneimittel
DE2635293A1 (de)	1977-05-12	Salzgemisch, insbesondere leicht assimilierbares arzneimittelgemisch mit erhoehter loeslichkeit, enthaltend kalziumsalze und/oder magnesiumsalze
DE938249C (de)	1956-01-26	Verfahren zur Herstellung von Dihydrocodeinhydrorhodanid
DE1770351C2 (de)	1983-02-03	2-0-Acyl-clindamycine, Verfahren zu deren Herstellung und diese Verbindungen enthaltende antibiotische Zubereitungen
DD142653A5 (de)	1980-07-09	Herstellungsmethode eines szintillographischen mittels
AT226705B (de)	1963-04-10	Verfahren zur Herstellung des neuen N, N-Diphenylisonikotinamids
DE217897C (fr)
DE2628042B2 (de)	1979-03-29	3-Amino-tricyclo [53.1.0.3A1 -undecan, dessen Säureadditionssalze und Verfahren zur Herstellung dieser Verbindungen
DE1593838C3 (de)	1974-11-07	Rutin-tri-(dihydroxypropyl)äther und Verfahren zu dessen Herstellung
AT361942B (de)	1981-04-10	Verfahren zur herstellung von neuen 9-substi- tuierten purinen und ihren salzen
DE1807165C (de)	1972-05-31	o^-Dimethoxy^H-l^-benzothiazin-4-one